Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,501 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04802824 | Measuring Treatment Response in Metastatic Renal Cell Cancer Using FPIA PET/CT | completed | — | 10 | Imperial College LondonOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02983279 | Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer | completed | N/A | 49 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 |
| clinicaltrials |
| NCT03076203 | Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) | completed | Phase 1 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04821297 | Linguistically-Tailored Mobile Intervention for the Improvement of Follow Up for Abnormal Pap Test Results | completed | N/A | 30 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03324373 | Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) | completed | Phase 1 | 11 | Yousef ZakhariaOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT02439060 | PUBMIC (Prophylactic Use of Biologic Mesh in Ileal Conduit) | completed | N/A | 156 | University of Southern CaliforniaOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06941038 | Intraoperative vs. Postoperative Intravesical Epirubicin Instillation for Prevention of Bladder Recurrence in High-Risk Upper Urinary Tract Urothelial Carcinoma(IEPBR) | completed | — | 270 | Ankara Etlik City HospitalOTHER_GOV | 1 | Apr 23, 2025 | clinicaltrials |
| NCT02025010 | Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT03661437 | Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy | completed | Early Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT04804813 | Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma | completed | — | 388 | TakedaINDUSTRY | 1 | Apr 11, 2025 | clinicaltrials |
| NCT05945108 | Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER | completed | — | 400 | AstraZenecaINDUSTRY | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03473756 | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma(FORT-2) | completed | Phase 1 | 37 | BayerINDUSTRY | 8 | Apr 9, 2025 | clinicaltrials |
| NCT02288247 | A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone(PRESIDE) | completed | Phase 3 | 688 | Astellas Pharma Europe Ltd.INDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT00436254 | Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer | completed | Phase 1 | 66 | University of WashingtonOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT03353831 | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | completed | Phase 3 | 574 | AGO Research GmbHINDUSTRY | 12 | Apr 6, 2025 | clinicaltrials |
| NCT03654638 | Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer | completed | Phase 2 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT04917744 | Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors | completed | — | 5 | Mayo ClinicOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT03173560 | Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma | completed | Phase 2 | 343 | Eisai Inc.INDUSTRY | 16 | Apr 1, 2025 | clinicaltrials |
| NCT03749707 | HPV in Sentinel Lymph Nodes of Cervical Cancer Patients | completed | N/A | 127 | University of AarhusOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05431777 | A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread | completed | — | 79 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06377683 | Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 8 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT00720941 | Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma(COMPARZ) | completed | Phase 3 | 1,110 | Novartis PharmaceuticalsINDUSTRY | 14 | Mar 30, 2025 | clinicaltrials |
| NCT04600336 | Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer | completed | Phase 2 | 88 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT01147822 | Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma | completed | Phase 2 | 367 | Novartis PharmaceuticalsINDUSTRY | 3 | Mar 28, 2025 | clinicaltrials |
| NCT05650164 | Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) | completed | — | 171 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06897306 | Gastric-type Endocervical Adenocarcinoma: a Population-based Cohort Study | completed | — | 317 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04049747 | Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer(IP4-CHRONOS) | completed | N/A | 100 | Imperial College LondonOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
| NCT02684227 | Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06883565 | Tertiary Lymphoid Structures Related Genes Predicting Prognosis in Clear Cell Renal Cell Carcinoma: a Retrospective Cohort Study | completed | — | 232 | Ding-Wei YeOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02365766 | Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects | completed | Phase 1 / Phase 2 | 83 | Jason R. BrownOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | completed | Phase 2 | 139 | EpicentRx, Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT03268382 | p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 | completed | Phase 2 | 36 | Aprea TherapeuticsINDUSTRY | 3 | Mar 17, 2025 | clinicaltrials |
| NCT06876584 | The CT-based Deep Learning Model Predicts Complications in Partial Nephrectomy | completed | — | 1,474 | Du LingzhiOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT03149822 | Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 45 | University of Colorado, DenverOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT03206047 | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2025 | clinicaltrials |
| NCT03891485 | Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy(REVOLUTION) | completed | — | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT02104063 | Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET](MRI-PET) | completed | — | 78 | Queen Mary University of LondonOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT03871036 | Improve Checkpoint-blockade Response in Advanced Urothelial Cancer(ICRA) | completed | Phase 1 / Phase 2 | 53 | The Netherlands Cancer InstituteOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03387761 | Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy(NABUCCO) | completed | Phase 1 | 54 | The Netherlands Cancer InstituteOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04428203 | Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer | completed | Phase 1 | 21 | Zin W MyintOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04871594 | Pre-operative Immunotherapy in Stage II-III Urothelial Cancer(TURANDOT) | completed | Phase 1 | 15 | The Netherlands Cancer InstituteOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT01767636 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02567409 | Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03805594 | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 43 | University of California, San FranciscoOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT05902637 | The Efficacy of Mapping for Cognitive Prostate Biopsy(MAPROSTATE) | completed | N/A | 175 | Marmara UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY | 35 | Feb 24, 2025 | clinicaltrials |
| NCT01130519 | A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer | completed | Phase 2 | 83 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 2, 2025source: clinicaltrials